Drugs / IM-1021
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06823167 | Feb 2025 → May 2028 expected | cancer, hematopoietic and lymphoid cell neoplasm | Immunome, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-11-06 | Immunome, Inc. | Results Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update immunome.com ↗
I am particularly pleased to share that we have observed objective responses at multiple dose levels in B-cell lymphoma patients treated with IM-1021. |
| 2025-01-13 | Immunome, Inc. | Regulatory Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference immunome.com ↗
Immunome also announced the FDA clearance of its IND submission for IM-1021, a ROR1-targeted ADC. |
| 2024-10-29 | Immunome, Inc. | Results Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021 immunome.com ↗
IM-1021 showed superior efficacy compared to zilovertamab vedotin in both the Jeko-1 mantle cell lymphoma model and the MDA-MB-468 triple negative breast cancer model. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-06 | Immunome, Inc. | Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update immunome.com ↗ |
| 2025-03-10 | Immunome, Inc. | Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC immunome.com ↗ |
| 2025-01-13 | Immunome, Inc. | Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference immunome.com ↗ |
| 2024-10-29 | Immunome, Inc. | Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021 immunome.com ↗ |
| 2024-10-18 | Immunome, Inc. | Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium immunome.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IM-1021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06823167 ↗ |
| Modality | Other / unclassified | “antibody-drug conjugate” NCT06823167 ↗ |
| Route | Intravenous | “IM-1021 will be administered intravenously” NCT06823167 ↗ |
| Target | ROR1 | “ROR1 directed antibody-drug conjugate” NCT06823167 ↗ |